Sarcopenia Market Insights Highlight Expanding Outlook Till 2034

Strategic Insights -

The sarcopenia market size was valued at ~USD 2,276 million in 2025 and is anticipated to reach USD 5,626 million by 2034 with a significant CAGR of 10.6% during the study period (2020-2034). This growth is driven by the increasing prevalence of sarcopenia, coupled with the development of novel therapies and treatments.

Sarcopenia is a condition characterized by the gradual loss of muscle mass, strength, and function, typically associated with aging. It can lead to physical frailty, reduced mobility, and an increased risk of falls and fractures. Early detection and management through exercise, diet, and, in some cases, medication, can help mitigate its effects.

The key companies developing therapies for sarcopenia include TNF Pharmaceuticals with MYMD-1/Isomyosamine, Biophytis with Sarconeos, and Lipocine with LPCN 1148. Additionally, several companies are working on early-stage sarcopenia treatments, such as ImmunoForge (Froniglutide), Rejuvenate Biomed (RJx-01), Keros Therapeutics (KER-065), and BPGbio (BPM 31510), among others.

The US had the largest market size for sarcopenia in 2025, valued at around USD ~1,500 million, with further growth anticipated by 2034. The UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK in 2024, followed by Germany, while Spain reported the lowest number of cases.

Key Takeaways:

  • The sarcopenia market size was valued at ~USD 2,276 million in 2025 and is anticipated to reach USD 5,626 million by 2034 with a CAGR of 10.6% during the study period.
  • In September 2025, Epirium Bio Inc. announced positive Phase 1 trial results for MF-300, a novel therapy under development for sarcopenia.
  • The key companies developing therapies for sarcopenia include TNF Pharmaceuticals with MYMD-1/Isomyosamine, Biophytis with Sarconeos, and Lipocine with LPCN 1148.
  • The US had the largest market size for sarcopenia in 2025, valued at around USD ~1,500 million, with further growth anticipated by 2034.
  • The UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK in 2024, followed by Germany, while Spain reported the lowest number of cases.
  • In 2024, the total number of diagnosed prevalent cases of sarcopenia across the 7MM was approximately 19,836,200, with projections indicating a rise throughout the study period.
  • The sarcopenia treatment pipeline is progressing with the development of novel therapies utilizing diverse mechanisms of action.

Statistics:

  • The sarcopenia market size was valued at ~USD 2,276 million in 2025 and is anticipated to reach USD 5,626 million by 2034.
  • The CAGR for the sarcopenia market during the study period (2020-2034) is 10.6%.
  • The US had the largest market size for sarcopenia in 2025, valued at around USD ~1,500 million.
  • The UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK in 2024.
  • The 65-69 age group had the highest number of sarcopenia cases in the US in 2024, estimated at approximately 4,520,200.
  • The estimated number of sarcopenia cases in Japan was around 5,225,100 in 2024.

Sources:

  • M2 PressWIRE: Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross (C)1994-2025 M2 COMMUNICATIONS RDATE:17102025
  • DelveInsight: Sarcopenia Market Forecast
  • DelveInsight: Sarcopenia Epidemiology
  • DelveInsight: Sarcopenia Epidemiology Forecast
  • DelveInsight: Sarcopenia Therapies and Key Companies
  • DelveInsight: Sarcopenia Market Outlook